Greene County homes for sale were listed at higher prices in May. Here's a look
The median home in Greene County listed for $339,500 in May, up 4.8% from the previous month's $323,825, an analysis of data from Realtor.com shows.
Compared to May 2024, the median home list price increased 3.9% from $326,625.
The statistics in this article only pertain to houses listed for sale in Greene County, not houses that were sold. Information on your local housing market, along with other useful community data, is available at data.news-leader.com.
Greene County's median home was 1,884 square feet, listed at $172 per square foot. The price per square foot of homes for sale is up 1% from May 2024.
Listings in Greene County moved steadily, at a median 42 days listed compared to the May national median of 51 days on the market. In the previous month, homes had a median of 43 days on the market. Around 504 homes were newly listed on the market in May, a 9.1% increase from 462 new listings in May 2024.
The median home prices issued by Realtor.com may exclude many, or even most, of a market's homes. The price and volume represent only single-family homes, condominiums or townhomes. They include existing homes, but exclude most new construction as well as pending and contingent sales.
Across the Springfield metro area, median home prices rose to $349,900, slightly higher than a month earlier. The median home had 1,885 square feet, at a list price of $173 per square foot.
In Missouri, median home prices were $309,999, a slight increase from April. The median Missouri home listed for sale had 1,760 square feet, with a price of $173 per square foot.
Throughout the United States, the median home price was $440,000, a slight increase from the month prior. The median American home for sale was listed at 1,840 square feet, with a price of $234 per square foot.
The median home list price used in this report represents the midway point of all the houses or units listed over the given period of time. Experts say the median offers a more accurate view of what's happening in a market than the average list price, which would mean taking the sum of all listing prices then dividing by the number of homes sold. The average can be skewed by one particularly low or high price.
The USA TODAY Network is publishing localized versions of this story on its news sites across the country, generated with data from Realtor.com. Please leave any feedback or corrections for this story here. This story was written by Ozge Terzioglu. Our News Automation and AI team would like to hear from you. Take this survey and share your thoughts with us.
This article originally appeared on Springfield News-Leader: Greene County homes for sale were listed at higher prices in May
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
30 minutes ago
- The Hill
Food and Drug Administration staff cuts may hinder US biomedical innovation
President Trump has rightly emphasized restoring America's economic and strategic independence — from reshoring pharmaceutical production to cutting regulatory red tape. But not all reforms are created equal. Recent restructuring efforts at the Food and Drug Administration may have been well-intentioned, but they risk undermining the very innovation and domestic capacity the president seeks to promote. In March, Health and Human Services Secretary Robert F. Kennedy Jr. announced a sweeping reorganization of the agency, which in part included the elimination of 3,500 full-time employees at the Food and Drug Administration — many of them senior scientific staff and experienced regulators who served as institutional pillars across drug review divisions. While we all support government efficiency and the secretary's efforts to create a gold-standard regulatory agency, the loss of this institutional memory risks hobbling the expedited pathways that small biotech firms rely on to deliver therapies for rare and life-threatening diseases. Unfortunately, the impact of these cuts is not theoretical. The Wall Street Journal has reported that some biotech firms have had to delay or cancel clinical trials due to lack of timely Food and Drug Administration guidance. One California biotech firm facing unpredictable delays has even turned to European regulators to move forward with a clinical trial — effectively offshoring American capital, investment and jobs. Others have reported receiving conflicting and confusing feedback from inexperienced FDA staff or no response at all on time-sensitive requests. But such issues don't just affect companies; they hurt patients, too. Innovation in gene therapies, cancer immunotherapies, and treatments for rare diseases depend on regulatory clarity and speed. Without senior staff to help clarify agency positions, decisions are either delayed or driven by less-experienced personnel unfamiliar with long-standing scientific standards. It's no surprise then that over 200 biotech CEOs, patient advocates and investors — many of them strong supporters of FDA modernization — have expressed their concerns in a letter to Senate Health, Education, Labor and Pensions Committee Chairman Bill Cassidy (R-La.). As a former member of Congress who sat on the Appropriations subcommittee overseeing the FDA, I have long supported targeted reforms to make the agency more nimble and responsive. But there is a fine line between streamlining operations and cutting the institutional capacity necessary to do the job. Removing experienced drug reviewers before an adequate backup plan can be put into place not only jeopardizes U.S. safety standards but also undermines our competitive edge. This matter is not merely a domestic problem; it's a global race. Since 2014, the number of biomedical drugs under development in China has grown twelvefold. Meanwhile, innovation in the U.S. has remained relatively flat. If trends continue, China could match or surpass the U.S. in biomedical innovation within the decade. We have seen this movie before — in semiconductors, in telecommunications, in clean energy. We cannot afford to let biotech go the same way. The Trump administration's tariff policy was designed to bring pharmaceutical manufacturing back to U.S. shores. But how can we expect capital to stay in the U.S. if our regulatory infrastructure cannot deliver? Delays and unpredictability at the FDA don't just slow down science — they push investors to look elsewhere. Even the user fee system — critical to funding timely drug reviews and a source of government revenue — has been impacted by the reduction in force. Staff who oversaw the reauthorization of the Prescription Drug User Fee Act have been laid off, raising questions about whether the agency will even be able to continue to collect user fees and whether these government cuts will actually end up costing taxpayers in the long run. Of course, Kennedy has long been a vocal advocate for health reform. His Make America Healthy Again agenda's focus on combatting chronic diseases and enhancing nutritional standards deserves attention. His focus for such reform is where his background and passion can lead to meaningful improvements. But when it comes to regulating complex biologics and therapeutics, we must be careful about taking actions that could inadvertently stymie scientific progress. President Trump's vision for American self-reliance will only succeed if it's built on a foundation of regulatory competence and stability. Swift actions should therefore be taken to restore the FDA's core functions, rehire critical staff and unfreeze the hiring of roles essential to America's leadership in biomedical science. The stakes — for patients, for innovation and for national security — are simply too high to ignore. John T. Doolittle is a former member of Congress who served on the Agriculture, Rural Development, FDA, and Related Agencies subcommittee of the Committee on Appropriations.
Boston Globe
an hour ago
- Boston Globe
Here's how Iran could retaliate after US strikes on its nuclear program
Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Ever since Israel started the war with a surprise bombardment of Iran's military and nuclear sites on June 13, Iranian officials from the supreme leader on down have warned the U.S. to stay out, saying it would have dire consequences for the entire region. Advertisement It should soon be clear whether those were empty threats or a grim forecast. Here's a look at what Iran's next move might be. Targeting the Strait of Hormuz The Strait of Hormuz is the narrow mouth of the Persian Gulf, through which some 20% of all oil traded globally passes, and at its narrowest point it is just 33 kilometers (21 miles) wide. Any disruption there could send oil prices soaring worldwide and hit American pocketbooks. Advertisement Iran boasts a fleet of fast-attack boats and thousands of naval mines that could potentially make the strait impassable, at least for a time. It could also fire missiles from its long Persian Gulf shore, as its allies, Yemen's Houthi rebels, have done in the Red Sea. The U.S., with its 5th Fleet stationed in nearby Bahrain, has long pledged to uphold freedom of navigation in the strait and would respond with far superior forces. But even a relatively brief firefight could paralyze shipping traffic and spook investors, causing oil prices to spike and generating international pressure for a ceasefire. Attacking US bases and allies in the region The U.S. has tens of thousands of troops stationed in the region, including at permanent bases in Kuwait, Bahrain, Qatar and the United Arab Emirates, Arab Gulf countries just across the Persian Gulf from Iran — and much closer than Israel. Those bases boast the same kinds of sophisticated air defenses as Israel, but would have much less warning time before waves of missiles or swarms of armed drones. And even Israel, which is several hundred kilometers (miles) further away, has been unable to stop all of the incoming fire. Iran could also choose to attack key oil and gas facilities in those countries with the goal of exacting a higher price for U.S. involvement in the war. A drone attack on two major oil sites in Saudi Arabia in 2019 — claimed by the Houthis but widely blamed on Iran — briefly cut the kingdom's oil production in half. Activating regional allies Iran's so-called Axis of Resistance — a network of militant groups across the Middle East, is a shadow of what it was before the war ignited by Hamas' Oct. 7, 2023, attack on Israel out of the Gaza Strip — but it still has some formidable capabilities. Advertisement Israel's 20-month war in Gaza has severely diminished the Palestinian Hamas and Islamic Jihad groups, and Israel mauled Lebanon's Hezbollah last fall, killing most of its top leadership and devastating much of southern Lebanon, making its involvement unlikely. But Iran could still call on the Houthis, who had threatened to resume their attacks in the Red Sea if the U.S. entered the war, and allied militias in Iraq. Both have drone and missile capabilities that would allow them to target the United States and its allies. Iran could also seek to respond through militant attacks further afield, as it is widely accused of doing in the 1990s with an attack on a Jewish community center in Argentina that was blamed on Tehran and Hezbollah. A sprint toward nuclear arms It could be days or weeks before the full impact of the U.S. strikes on Iran's nuclear sites is known. But experts have long warned that even joint U.S. and Israeli strikes would only delay Iran's ability to develop a weapon, not eliminate it. That's because Iran has dispersed its program across the country to several sites, including hardened, underground facilities. Iran would likely struggle to repair or reconstitute its nuclear program while Israeli and U.S. warplanes are circling overhead. But it could still decide to fully end its cooperation with the International Atomic Energy Agency and abandon the the Nuclear Nonproliferation Treaty. North Korea announced its withdrawal from the treaty in 2003 and tested a nuclear weapon three years later, but it had the freedom to develop its program without punishing airstrikes. Advertisement Iran insists its program is peaceful, though it is the only non-nuclear-armed state to enrich uranium up to 60%, a short, technical step away from weapons-grade levels of 90%. U.S. intelligence agencies and the IAEA assess Iran hasn't had an organized military nuclear program since 2003. Israel is widely believed to be the only nuclear-armed state in the Middle East but does not acknowledge having such weapons. Gambrell reported from Dubai, United Arab Emirates.
Business Insider
2 hours ago
- Business Insider
FedEx founder Fred Smith is dead at 80
Frederick Wallace Smith, the founder and former CEO of FedEx, died Saturday at the age of 80. Smith's death was confirmed by FedEx in a statement. He is survived by his wife, nine of his 10 children, and numerous grandchildren. "Fred was more than just the pioneer of an industry and the founder of our great company. He was the heart and soul of FedEx — its PSP culture, values, integrity, and spirit," Smith's successor, CEO Raj Subramaniam, said. "He was a mentor to many and a source of inspiration to all." Smith, who built FedEx over 50 years ago, was a celebrated entrepreneur who often served as a bellwether for the US economy and global trade for politicians and the media. He was called to the White House as recently as March 2022 to discuss the economic matters of the day. Over the years, he wrote op-eds for the Wall Street Journal, pushing policies, nudging presidents, and lodging grievances. "History shows that trade made easy, affordable, and fast—political obstacles notwithstanding—always begets more trade, more jobs, more prosperity," he said at a Yale University class of 1966 reunion in 2016. He built FedEx in his hometown of Memphis, where he was the top business leader for decades. "Memphis is kind of a one-name town. There's Elvis. There's Cybill. And there's Fred," said Tennessee Congressman Steve Cohen when introducing Smith at a congressional hearing in 2021. In an age where tech founders and CEOs have attained celebrity status, Smith represented a more traditional version of the quintessential American dream, favoring visits to Washington over Hollywood. Smith announced he would step down as CEO in March 2022, handing the reins to lieutenant Raj Subramaniam and taking on the role of executive chairman. "FedEx has changed the world by connecting people and possibilities for the last 50 years," Smith said in a statement announcing the change. He said he planned to spend his time focused on sustainability, innovation, and public policy going forward. Founding FedEx Smith was born in 1944 and served in the US Marine Corps during the Vietnam War. In 1971, at the age of 27, he founded Federal Express with $4 million in inheritance and $91 million in venture capital — an immense sum at the time. Working from an idea he developed as a student at Yale, Smith based his logistics network on a bank clearing house: Packages would go first to FedEx's central location and to their final destination the next day. Today, Smith is largely credited with inventing the concept of guaranteed overnight delivery. In the early days, FedEx focused on the medical and manufacturing industries, where parts and materials are often needed urgently. The company bought its first plane in 1973, turned its first profit after four years in business, and only grew from there. Smith said his time in the Marine Corps gave him a high tolerance for risk. Business decisions felt light compared to the life-and-death choices he had made in Vietnam. At one point in the early days, FedEx had just $5,000 left. Smith took the money, flew to Las Vegas, turned it into $27,000 playing blackjack, and used the windfall to pay fuel suppliers. In the late 1970s, airline deregulation allowed FedEx to buy hundreds of planes and construct an international network. In a 1983 interview, 60 Minutes' Morley Safer asked the 39-year-old Smith if he ever doubted FedEx would be a success. "Well, that would be an understatement," Smith replied with a laugh. Starting around that time, Smith grew his company with dozens of acquisitions. His 1989 purchase of cargo airline Flying Tigers made FedEx the largest full-service, all-cargo airline in the world, which remained for decades, and still is. He bought delivery firm RPS in 1997, which would become FedEx Ground, and Kinko's in 2004 to form the FedEx Office retail store network. By 2021, the company was shipping roughly 3 billion packages every year, with 688 planes in 220 countries and territories. Taking on Washington and New York Smith was an outspoken advocate for American business around the world throughout his more than 50 years as CEO. He served as president of the US-China Business Council when China became a member of the WTO, and was close friends with former President George W. Bush. Bush wrote in his 2010 memoir that Smith was his top pick for Secretary of Defense in both of his terms, but the executive declined due to the failing health of his daughter Windland Smith Rice, who died in 2005. Smith was also national cochair of John McCain's presidential campaign committee in 2008. Though a Republican, Smith publicly disagreed with President Donald Trump's use of tariffs and opposition to multilateral trade deals. "Trade is what's made America great over the years," Smith told CBS's "This Morning" in 2017. Smith's disagreements with the Trump administration were, however, less heated than his related spat with The New York Times, which centered on the Trump administration's tax policies. Smith publicly sparred with the paper when it published a 2017 story detailing how FedEx was able to pay zero taxes after working to encourage Trump's tentpole corporate tax cuts. Smith called the story "distorted and factually incorrect," and challenged publisher A.G. Sulzberger to a public debate, which the paper declined, calling Smith's response "colorful" and a "stunt." In a Wall Street Journal op-ed, Smith accused the paper of "printing selected facts, connecting unrelated events, and implying nefarious activities when there were none whatever." Evolution in the age of Amazon In its early decades, FedEx chiefly moved deliveries from one business to another. The rise of e-commerce changed that and triggered some of the biggest changes in the company's history, though some experts say Smith didn't pivot quickly enough. In 2019, the company began to integrate its disparate Ground and Express services somewhat and moved away from the US Postal Service in an effort to boost its own efficiency. That was also the year Smith went from a partner of Amazon to a fierce adversary. The CEO had shirked years of questions as to whether Amazon's growing logistics empire was a threat to FedEx — until Amazon named logistics companies as competitors in an annual filing with the SEC. FedEx then cut ties with the internet giant, the only carrier to do so. Smith described the battle for e-commerce dominance as a war in which he was betting on Amazon's opponents. Smith's sometimes gruff, no-nonsense style was frequently on display when discussing Amazon. He once called then-Amazon operations lead Dave Clark a "smartass" in the Wall Street Journal." Smith and his then-COO Raj Subramaniam, who will succeed Smith on June 1, 2022, designed the moves away from Amazon and the USPS. Leaving a mark on the US economy Smith built a delivery company into a universally recognized cultural icon. The plane that delivered the first FedEx package sits in the Smithsonian's Air and Space Museum. The current FedEx logo, introduced in 1994, is a classic of graphic design and the focus of frequent internet fascination over the arrow created by the "E" and "x." Plus, a FedEx package was at the emotional core of the Oscar-nominated Tom Hanks film "Cast Away" (in which Smith had a cameo). "I always told Tom Hanks I thought my 18 seconds in there sort of made his career," he said in the same 2017 CBS interview, with his signature deadpan delivery. FedEx's name is on an NFL stadium — FedEx Field, outside Washington, DC, home to the Washington Commanders, of which Smith was once a minority owner. His son, Arthur, is the head coach for the Atlanta Falcons. Son Richard Smith is set to take over as CEO of FedEx Express at the end of 2022, and daughter Samantha Smith works in government affairs for FedEx in Washington, DC. Inside FedEx, Fred Smith was revered. He was referred to as "Mr. Smith" or "the chairman" and was known for eschewing some of the fineries his level of success usually entails. He commuted the short distance from his home to his Memphis HQ in his own modest car. Smith solidified FedEx and logistics as a lynchpin in the American economy. The role of package delivery companies changed over the course of Smith's career, but perhaps never more so than during the coronavirus pandemic beginning in 2020. FedEx and its competitors played crucial roles in the delivery of critical supplies. When vaccines were ready for distribution in early 2021, FedEx carried some of the first shipments. In 2021 alone, FedEx delivered roughly 300 million COVID-19 vaccines in more than 50 countries and territories around the world. "We're honored to be a part of this great mission to remove the scourge from our society," said Smith at a 2020 meeting with then-Vice President Mike Pence to discuss Operation Warp Speed vaccine distribution efforts.
